Gallasch G, Dörfer C, Schmitt T, Stage A
Klin Monbl Augenheilkd. 1985 Jul;187(1):30-5. doi: 10.1055/s-2008-1050983.
In a clinically controlled double-blind study it was demonstrated that tri-(hydroxyethyl)-rutin is not capable of significantly improving blood viscosity or one of its constituent factors. On the basis of data from 58 patients, none of whom was under 43 years old, it was possible to show that the substance tested has no favorable influence on plasma viscosity, erythrocyte deformability and aggregation, or on the concentration of plasma proteins which promote aggregation. Thus, in the very group of patients for whom an improvement in blood flow properties by means of oral administration of tri-(hydroxyethyl)rutin had been hoped for, no therapeutic effect could be demonstrated.
在一项临床对照双盲研究中表明,三(羟乙基)芦丁不能显著改善血液粘度或其构成因素之一。基于58例年龄均不低于43岁患者的数据,结果显示所测试的该物质对血浆粘度、红细胞变形性和聚集性,或对促进聚集的血浆蛋白浓度均无有利影响。因此,对于原本期望通过口服三(羟乙基)芦丁改善血流特性的这组患者,未显示出治疗效果。